BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 25847683)

  • 1. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
    Li C; Wang W; Xie L; Luo X; Cao X; Wan M
    Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.
    Yang H; Dong J; Xiong W; Fang Z; Guan H; Li F
    Ann N Y Acad Sci; 2016 Dec; 1385(1):41-52. PubMed ID: 27723935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of histone deacetylase inhibitor Scriptaid and parathyroid hormone on osteocyte functions and metabolism.
    Sun N; Uda Y; Azab E; Kochen A; Santos RNCE; Shi C; Kobayashi T; Wein MN; Divieti Pajevic P
    J Biol Chem; 2019 Jun; 294(25):9722-9733. PubMed ID: 31068415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation.
    Baertschi S; Baur N; Lueders-Lefevre V; Voshol J; Keller H
    J Biol Chem; 2014 Sep; 289(36):24995-5009. PubMed ID: 25012661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of the SOST bone enhancer by PTH using MEF2 transcription factors.
    Leupin O; Kramer I; Collette NM; Loots GG; Natt F; Kneissel M; Keller H
    J Bone Miner Res; 2007 Dec; 22(12):1957-67. PubMed ID: 17696759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.
    Li C; Xing Q; Yu B; Xie H; Wang W; Shi C; Crane JL; Cao X; Wan M
    J Bone Miner Res; 2013 Oct; 28(10):2094-108. PubMed ID: 23609180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.
    Silvestrini G; Ballanti P; Leopizzi M; Sebastiani M; Berni S; Di Vito M; Bonucci E
    J Mol Histol; 2007 Aug; 38(4):261-9. PubMed ID: 17549589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
    Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
    J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
    Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
    Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIKs control osteocyte responses to parathyroid hormone.
    Wein MN; Liang Y; Goransson O; Sundberg TB; Wang J; Williams EA; O'Meara MJ; Govea N; Beqo B; Nishimori S; Nagano K; Brooks DJ; Martins JS; Corbin B; Anselmo A; Sadreyev R; Wu JY; Sakamoto K; Foretz M; Xavier RJ; Baron R; Bouxsein ML; Gardella TJ; Divieti-Pajevic P; Gray NS; Kronenberg HM
    Nat Commun; 2016 Oct; 7():13176. PubMed ID: 27759007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of LRP6 regulate PTH-induced cAMP generation.
    Shi C; Li J; Wang W; Cao W; Cao X; Wan M
    Ann N Y Acad Sci; 2011 Nov; 1237():39-46. PubMed ID: 22082363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-cadherin restrains PTH activation of Lrp6/β-catenin signaling and osteoanabolic action.
    Revollo L; Kading J; Jeong SY; Li J; Salazar V; Mbalaviele G; Civitelli R
    J Bone Miner Res; 2015 Feb; 30(2):274-85. PubMed ID: 25088803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.
    Nakatani T; Chen T; Johnson J; Westendorf JJ; Partridge NC
    J Bone Miner Res; 2018 Jul; 33(7):1362-1375. PubMed ID: 29544022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
    Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
    J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does osteocytic SOST suppression mediate PTH bone anabolism?
    Kramer I; Keller H; Leupin O; Kneissel M
    Trends Endocrinol Metab; 2010 Apr; 21(4):237-44. PubMed ID: 20074973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
    Bonnet N; Conway SJ; Ferrari SL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15048-53. PubMed ID: 22927401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOST is a target gene for PTH in bone.
    Keller H; Kneissel M
    Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor.
    Delgado-Calle J; Tu X; Pacheco-Costa R; McAndrews K; Edwards R; Pellegrini GG; Kuhlenschmidt K; Olivos N; Robling A; Peacock M; Plotkin LI; Bellido T
    J Bone Miner Res; 2017 Mar; 32(3):522-535. PubMed ID: 27704638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats.
    Jia HB; Ma JX; Ma XL; Yu JT; Feng R; Xu LY; Wang J; Xing D; Zhu SW; Wang Y
    Osteoporos Int; 2014 Dec; 25(12):2743-54. PubMed ID: 25074352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D
    St John HC; Hansen SJ; Pike JW
    J Steroid Biochem Mol Biol; 2016 Nov; 164():277-280. PubMed ID: 26361013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.